Tag: TOTUM-854

Valbiotis Announces Approval to Launch the Two Phase II/III INSIGHT and INSIGHT 2 Clinical Studies, the Last Step in the Development of TOTUM•854 For the Reduction of Blood Pressure

Coronary/Structural Heart by 0 comments

These authorizations enable the simultaneous launch of recruitment for these international studies, which should be completed in the first half of 2023. The INSIGHT and INSIGHT 2 randomized, placebo-controlled studies are designed to include a total of 800 volunteers with […]

Continue Reading →

Valbiotis Announces That It Has Submitted to the Competent Authorities the Three Clinical Protocols for TOTUM•854 Indicated in the Reduction of Blood Pressure and Presents Its Comprehensive Clinical Development Plan

Rhythm by 0 comments

The INSIGHT international, multicenter, randomized, placebo-controlled pivotal Phase II/III clinical study will be conducted with a 3.7 g/day dose of TOTUM•854 on 400 volunteers; The INSIGHT 2 international, multicenter, randomized, placebo-controlled Phase II/III clinical study will be conducted with a […]

Continue Reading →